Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ImmunityBio, Inc. (IBRX : NSDQ)
 
 • Company Description   
ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest Inc., is based in CULVER CITY, Calif.

Number of Employees: 680

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.98 Daily Weekly Monthly
20 Day Moving Average: 12,387,469 shares
Shares Outstanding: 984.97 (millions)
Market Capitalization: $1,950.23 (millions)
Beta: 0.03
52 Week High: $4.27
52 Week Low: $1.83
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.91% -13.77%
12 Week -18.85% -20.16%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3530 JOHN HOPKINS COURT
-
SAN DIEGO,CA 92121
USA		 ph: 844-696-5235
fax: -		 investors@immunitybio.com http://www.immunitybio.com
 
 • General Corporate Information   
Officers
Richard Adcock - Chief Executive Officer; President and Director
Patrick Soon-Shiong - Global Chief Scientific and Medical Officer; and
David C. Sachs - Chief Financial Officer
Regan J. Lauer - Chief Accounting Officer
Barry J. Simon - Chief Corporate Affairs Officer and Director

Peer Information
ImmunityBio, Inc. (CORR.)
ImmunityBio, Inc. (RSPI)
ImmunityBio, Inc. (CGXP)
ImmunityBio, Inc. (BGEN)
ImmunityBio, Inc. (GTBP)
ImmunityBio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45256X103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/02/26
Share - Related Items
Shares Outstanding: 984.97
Most Recent Split Date: (:1)
Beta: 0.03
Market Capitalization: $1,950.23 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.32 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/02/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 23.62
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 30.00%
Sales Growth
vs. Year Ago Period: 425.07%
vs. Previous Quarter: 21.33%
ROE
12/31/25 - -
09/30/25 - -
06/30/25 - -
ROA
12/31/25 - -
09/30/25 - -98.33
06/30/25 - -113.86
Current Ratio
12/31/25 - -
09/30/25 - 5.77
06/30/25 - 4.11
Quick Ratio
12/31/25 - -
09/30/25 - 5.65
06/30/25 - 3.98
Operating Margin
12/31/25 - -
09/30/25 - -478.73
06/30/25 - -730.90
Net Margin
12/31/25 - -
09/30/25 - -422.28
06/30/25 - -648.57
Pre-Tax Margin
12/31/25 - -
09/30/25 - -422.38
06/30/25 - -648.65
Book Value
12/31/25 - -
09/30/25 - -0.53
06/30/25 - -0.65
Inventory Turnover
12/31/25 - -
09/30/25 - 0.05
06/30/25 - 0.03
Debt-to-Equity
12/31/25 - -
09/30/25 - -
06/30/25 - -
Debt-to-Capital
12/31/25 - -
09/30/25 - -
06/30/25 - -
 

Powered by Zacks Investment Research ©